UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care


ABSTRACT

The risks of poor transition include delayed and inappropriate transfer that can result in disengagement with healthcare. Structured transition care can improve control of chronic digestive diseases and long-term health-related outcomes. These are the first nationally developed guidelines on the transition of adolescent and young persons (AYP) with chronic digestive diseases from paediatric to adult care. They were commissioned by the Clinical Services and Standards Committee of the British Society of Gastroenterology under the auspices of the Adolescent and Young Persons (A&YP) Section. Electronic searches for English-language articles were performed with keywords relating to digestive system diseases and transition to adult care in the Medline (via Ovid), PsycInfo (via Ovid), Web of Science and CINAHL databases for studies published from 1980 to September 2014. The quality of evidence and grading of recommendations was appraised using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. The limited number of studies in gastroenterology and hepatology required the addition of relevant studies from other chronic diseases to be included.

These guidelines deal specifically with the transition of AYP living with a diagnosis of chronic digestive disease and/or liver disease from paediatric to adult healthcare under the following headings:  
1. Patient populations involved in AYP transition  
2. Risks of failing transition or poor transition  
3. Models of AYP transition  
4. Patient and carer/parent perspective in AYP transition  
5. Surgical perspective

SUMMARY OF RECOMMENDATIONS

Recommendations: patient populations involved in adolescent and young person transition

We recommend that adolescent and young person (AYP) with IBD, coeliac disease and chronic liver disease should be involved in formal transition arrangements (Grading of Recommendations Assessment, Development and Evaluation (GRADE) recommendation: strong (C)).

Recommendations: risk of failing or poor AYP transition

1. We recommend the use of structured transition programmes to improve control of chronic gastrointestinal (GI) disease in AYP (GRADE recommendation: strong (C)).
2. We recommend the use of structured transition programmes to enhance adherence to medications, clinic attendance and clinical outcomes including organ survival in liver transplantation (GRADE recommendation: strong (C)).
3. We suggest that the use of structured transition programmes may increase disease related knowledge in patients and carers/parents (GRADE recommendation: weak (C)).
4. We suggest that a structured transition programme may improve psychological outcome and health-related quality of life in chronic GI diseases (GRADE recommendation: weak (D)).
5. We suggest that the use of a structured transition programme may reduce adverse outcomes such as hospitalisation, surgery and radiation exposure in GI disease (GRADE recommendation: weak (C)).

Recommendations: models of AYP transition

1. We suggest that an overlap with both paediatric and adult gastroenterology care is a core element of every structured transition service (GRADE recommendation: weak (C)).
2. We suggest that while there are numerous models of transition there is no evidence to support a particular type (GRADE recommendation: weak (C)).
3. We recommend an effective transition model may benefit from inclusion of the following elements (GRADE recommendation: strong (D)):  
   A. Flexible timing of transition  
   B. A named transition coordinator to oversee the process  
   C. Individualisation of the transition model based on local expertise, staffing, resources and geography  
   D. Assessment of readiness for transfer  
   E. Disease-specific education programme
4. We recommend information technology as an effective and cost-efficient tool to facilitate transition (GRADE recommendation: strong (C)).
5. We recommend that AYP’s self-efficacy is enhanced by the use of virtual intervention and electronic communication (GRADE recommendation: strong (C)).
6. We recommend regular audit of the transition service in order to improve the service,
outcomes and assess key performance indicators (GRADE
recommendation: strong (D)).

Recommendations: patient and carer/parent perspective in
AYP transition
1. We suggest that healthcare professionals (HCPs) consider
concerns of AYP and their carers/parents during transition
and identify when additional emotional and psychological
support is required (GRADE recommendation: weak (D)).
2. We suggest that HCPs maintain the goal of empowering
the AYP to become independent while acknowledging the carer/
parent perspectives (GRADE recommendation: weak (C)).
3. We recommend that AYP identified as at risk of non-
adherence may benefit from targeted specific educational
and organisational interventions (GRADE recommendation:
strong (C)).
4. We recommend that disease-specific information and educa-
tion be appropriate for the AYP developmental stage and
this should be reassessed over the period of transition
(GRADE recommendation: strong (C)).
5. We suggest the transition process addresses the AYP’s
lifestyle, future health concerns, educational/employment goals,
psychosocial health, sexuality and reproduction (GRADE
recommendation: weak (D)).

GUIDELINE DEVELOPMENT
Introduction
The requirement for the consensus guidelines on this topic was
highlighted by a national survey of physician and nurse attitudes
to transition conducted by the Adolescent and Young Persons
(AYP) Section of the British Society of Gastroenterology
(BSG).1 2 There is currently no European consensus guideline
available for clinicians working in this field, although in 2015
the Italian Societies of Gastroenterology published a position
statement,3 as have the North America Society for Paediatric
Gastroenterology, Hepatology and Nutrition in 1993.4
The guideline proposal was reviewed and accepted by the Clinical
Services and Standards Committee (CSSC) in 2014. Members
of the guideline committee were selected after an open invita-
tion for expressions of interest and divided into multidisciplinary
subgroups. The authors drafted a preliminary guideline
document following the ‘BSG Guideline Advice’ document.5 6
The draft guidelines were submitted for review by BSG AYP
Section, CSSC and BSG Council and revised in response to
their comments.

Data sources and search strategy
A systematic literature search was undertaken by a medical librar-
ian (RF) using four relevant databases, Medline (via Ovid),
Embase, Web of Science and CINAHL, aiming to capture all rele-
vant studies across disciplines including paediatric and adult
gastroenterology from 1980 to September 2014. MeSH search
terms relating to digestive system diseases (“gastrointestinal
disease”, “hepatological disease”, “liver disease”, “digestives
system disease”), transition to adult care (“transition clinic”, “tran-
sition” “transition process”, “transition care”, “transfer”), adoles-
cent (“adolescent”, “young adult” (were entered and combined,
and limited to ‘adolescent’ and ‘young adult’ (see online
supplementary appendix 1)). Following this, section working
groups reviewed all relevant articles and any additional records
identified through other sources in an iterative way, drawing on
clinical expertise in the field to draw on key publications related to
AYP transition in non-GI or hepatology disorders.

Denotes terms where truncation has been used.

Study eligibility and selection criteria
Members of the guideline group determined study eligibility for
inclusion in the final consensus. Studies were initially screened
independently by all members of each subgroup. Decisions
regarding study inclusion were made by consensus within each
subgroup, with final decisions regarding study inclusion made by
the relevant chair. Studies were included if (a) published in full
and (b) written in English. Studies were excluded if (a) they were
case studies or not empirical studies (eg, narrative reports) and (b)
they were only published in abstract. Additional studies of interest
were identified by hand searches of bibliographies and cited
references and by consultation with clinical experts in the field.

Data extraction and quality assessment
Of 639 studies identified, a formal assessment of quality was
conducted using the GRADE system.7 8

Assessing the quality of the guidelines: the Agree II
instrument
The Agree II instrument is the recognised and accepted method
of assessing the quality of clinical guidelines.9 Six domains are
listed and the position of the current guideline in these domains
is stated:
1. Scope and purpose
The aim of the guideline is to provide clinical guidelines
based on current available literature for the care of AYP as they
progress from paediatric health services through to adult care,
for clinicians and other health professionals in gastroenterology
and hepatology.
2. Guideline development group membership and stakeholder
involvement
Membership of the guideline development group included
paediatric and adult gastroenterologists and hepatologists, spe-
cialist nurses and dieticians who were selected after an open call
for participation was published in the BSG newsletter. The
group also included patient and parent members as well as
representatives from appropriate patient organisations who were
invited to participate by the chairperson. The guideline develop-
ment group had three face-to-face meetings (30 September
2014, 20 January 2015 and 5 May 2015) where the scope and
remit of the guideline was planned and progress reviewed at key
stages. The guideline development group was divided into four
multidisciplinary subgroups; patient populations, risks of poor
transition, models of transition and, finally, the patient and
parent perspective (see online supplementary appendix 2). Each
subgroup had a nominated chairperson (RKR, DRG, SS and
PJS, respectively) with the responsibility of overseeing the
review of relevant literature and production of draft recommen-
dations and accompanying text for publication for that section
(see online supplementary appendix 2).
3. Rigour of development
The guideline development group met regularly for discussion
via face-to-face meetings and teleconferences during the period
from September 2014 to September 2015. The guidelines rely
on a formal assessment of study quality that was conducted
using the GRADE system.7 8 GRADE was used to determine (a)
quality of studies included into high (A), moderate (B), low (C)
or very low (D); and (b) assess guideline recommendations and
classify them as either STRONG or WEAK (tables 1 and 2).
In the guideline, we have stated the recommendations and the
associated GRADE of evidence together. Practice points were
included based on expert clinical experience and consensus of
opinion rather than these being supported by clinical research,
as used in European Crohn’s and Colitis Organisation (ECCO)
The review resulted in the writing committee (AJB, PJS, providing detailed feedback to the Guideline Development publication in July 2016. This involved peer review by the CSSC and BSG Council for consideration of consensus for these to be included. The guidelines were subject to group felt there was enough expert clinical experience and appropriate research, but where the guideline development formal recommendations were not possible due to a paucity of >80% were in agreement. Practice points were used where.

### Table 2

<table>
<thead>
<tr>
<th>Study design</th>
<th>Initial quality of a body of evidence</th>
<th>Modify the initial quality of a body of evidence</th>
<th>Quality of body of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomised controlled trials</td>
<td>High★★★★</td>
<td>Rate lower if Risk of bias: Large effect</td>
<td>High (A)★★★★</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious: +1 +1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious: +2 Very large</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inconsistency: Dose response</td>
<td>Moderate (B)★★★</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious: +1 Evidence of a gradient</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious:</td>
<td></td>
</tr>
<tr>
<td>Observational studies/qualitative studies</td>
<td>Low★★</td>
<td>Indirectness: All plausible residual confounding</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Imprecision: +1 would reduce a demonstrated effect</td>
<td>Low (C)★★</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Publication bias: +1 would suggest a spurious effect if no effect observed</td>
<td>Very low (D)★</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Likely:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very likely:</td>
<td></td>
</tr>
</tbody>
</table>

Table 1  Individual studies included in the guideline are formally assessed using the GRADE system with the quality of the body evidence rated, from ‘high’ (A) to ‘very low’ (D).

<table>
<thead>
<tr>
<th>Study design</th>
<th>Initial quality of a body of evidence</th>
<th>Modify the initial quality of a body of evidence</th>
<th>Quality of body of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomised controlled trials</td>
<td>High★★★★</td>
<td>Rate lower if Risk of bias: Large effect</td>
<td>High (A)★★★★</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious: +1 +1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious: +2 Very large</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inconsistency: Dose response</td>
<td>Moderate (B)★★★</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious: +1 Evidence of a gradient</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious:</td>
<td></td>
</tr>
<tr>
<td>Observational studies/qualitative studies</td>
<td>Low★★</td>
<td>Indirectness: All plausible residual confounding</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Imprecision: +1 would reduce a demonstrated effect</td>
<td>Low (C)★★</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Serious:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very serious:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Publication bias: +1 would suggest a spurious effect if no effect observed</td>
<td>Very low (D)★</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1 Likely:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2 Very likely:</td>
<td></td>
</tr>
</tbody>
</table>

Table 2  Guideline recommendations are classified as either strong or weak by determining the balance of desirable and undesirable outcomes using the GRADE system.

### Rating the strength of a recommendation: balancing desirable and undesirable outcomes

<table>
<thead>
<tr>
<th>Strong recommendation</th>
<th>Weak recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desirable outcomes +++ &gt; undesirable outcomes +</td>
<td>Desirable outcomes ++ &gt; undesirable outcomes +</td>
</tr>
<tr>
<td>Examples of desirable outcomes +</td>
<td>Examples of undesirable outcomes +</td>
</tr>
<tr>
<td>Increased longevity</td>
<td>Decreased longevity</td>
</tr>
<tr>
<td>Reduction in morbid events</td>
<td>Immediate serious complications</td>
</tr>
<tr>
<td>Intervention designed to prevent complications</td>
<td>Short-term relatively minor side effects</td>
</tr>
<tr>
<td>Resolution of symptoms</td>
<td>Long-term rare serious adverse events</td>
</tr>
<tr>
<td>Improved quality of life</td>
<td>Impaired quality of life</td>
</tr>
<tr>
<td>Decreased resource use</td>
<td>Inconvenience/hassle</td>
</tr>
<tr>
<td>Increased resource use</td>
<td></td>
</tr>
</tbody>
</table>

and European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPAGHAN) guidelines.

Face-to-face meetings were held to agree the recommendations. Areas of disagreement about the recommendation grade were subject to discussion and, where necessary, voting by members of the guidelines group with consensus achieved when >80% were in agreement. Practice points were used where formal recommendations were not possible due to a paucity of appropriate research, but where the guideline development group felt there was enough expert clinical experience and consensus for these to be included. The guidelines were subject to peer review by the CSSC and BSG Council for consideration of publication in July 2016. This involved five expert reviewers providing detailed feedback to the Guideline Development Group. The review resulted in the writing committee (AJB, PJS, JOL, SAM) undertaking changes and improvement in the structure and content of the guideline that underwent subsequent approval by the Chair of the CSSC. The updated guideline was reviewed by all members of the Guideline Development Group prior to submission for publication in September 2016.

4. **Clarity and presentation**

Recommendations are intended to be specific to particular areas of transition and the process of transition in order to provide clinicians and allied health professionals with guidance to facilitate development of transition facilities with a local setting and context.

5. **Applicability**

Within the guidance we have discussed organisational changes that may be required to apply the recommendations and identified areas suitable for monitoring, audit and service improvement.

6. **Editorial independence and conflict of interest**

Guideline group members have declared any conflicts of interest, which are detailed at the end of the guideline.

### PATIENT POPULATIONS INVOLVED IN AYP TRANSITION

**Transition for GI disease areas**

Until recently, there has been a lack of transition services for AYP patients with chronic GI and liver diseases in the UK. The most frequent GI areas where transition arrangements exist are IBD followed by chronic liver disease comprising both transplanted and non-transplanted patients. A very small number of patients with complex nutritional needs are transferred or transitioned on an ad hoc basis although there are not dedicated clinics for these patient groups in the UK. Until recently, the majority of patients with coeliac disease and other common GI illnesses (constipation, GORD), together with simple functional GI disorders, have been transferred from paediatric to adult care or discharged from paediatric care with the expectation that the primary care physician will refer to an appropriate adult consultant if required. However, after the initial evidence search for this guideline was completed in 2016 the first consensus guidelines regarding transition in coeliac disease recommend structured transition for this patient group, and there has been recent interest in transition.
care for emerging diseases like eosinophilic oesophagitis\(^\text{15}\) and complex functional GI disorders.

**Prevalence of GI disease in this population**

While published data exist on the prevalence of specific GI and liver disease in AYPs, the actual numbers of patients who move from paediatric to adult care with or without transition annually have not been recorded systematically. This is important as it will determine the potential impact of recommendations to implement a transition service for a specific disease. An estimate based on extrapolation from audits, surveys or expert opinion is provided in table 3. Due to the comparatively larger sizes of the patient populations—transition has to date been more frequently undertaken in the IBD and liver disease patient populations, but is of increasing importance in other GI diseases such as coeliac disease\(^\text{14}\) and in complex functional GI disorders. However, the true requirement for transition care among AYP with GI disease has still to be accurately defined and data on the number of transition clinics currently supporting AYPs through the transition process are not available to be able to estimate any shortfall in service provision. However, these figures are likely to be underestimating the true prevalence of AYPs requiring formal transition into adult services. The demand for specialist nutrition for paediatric GI and surgical disorders has risen in recent years, suggesting that increasing numbers of AYP patients may survive and require transition to adult services. Furthermore, the number of complex enteral nutrition patients will be significantly higher than those requiring parenteral nutrition support. Children with complex motility disorders will make up a small proportion of these patients\(^\text{16}\) and therefore may require formal transitioning into adult care with multidisciplinary support given their symptomatology, nutrition support and psychological comorbidity can be difficult to manage.

**Disease course and differences between AYP and adults**

For specific GI diseases, there are documented variations in prognosis and clinical course when the disease presents in childhood compared with adulthood. This has clear relevance for the AYP transition process in these diseases. There are also clear differences in diagnostic and therapeutic IBD management dependent on age at diagnosis with a higher use of exclusive enteral nutrition in children with Crohn’s disease and general anaesthetic use for endoscopy in children compared with sedation in adults. Furthermore, children presenting with IBD have a more extensive disease phenotype and rapid early progression, although there no clear differences reported in the rate of disease complications.\(^\text{19}\)

Although the clinical course of coeliac disease presenting in childhood is often more severe than that presenting later in life, it is difficult to predict outcomes dependent on age at diagnosis with sparse research in this area. There are no studies that assess the benefit or risk of good versus poor disease control during the transition from paediatric to adult care. However, there are differences in management as in children the diagnosis of coeliac disease is often based on serology with supportive investigations without the need for duodenal biopsy, whereas histological evaluation is always recommended in adults.\(^\text{20}\) The use of psychological management for functional GI illness in paediatrics is higher than adult practice. Outside the GI tract, the most common indication for liver transplant in children is for congenital reasons (biliary atresia) compared with acquired liver disease in adulthood.

**Recommendations and practice points**

We recommend that AYP with IBD, coeliac disease and chronic liver disease should be involved in formal transition arrangements (GRADE recommendation: strong (C)).

**Practice points**

- AYP with other chronic GI and liver conditions, including complex functional disorders, are likely to benefit from formal transition arrangements and may be incorporated into existing transition services.
- HCPs involved in the management of AYP should be aware of the differences between classification, diagnostic methods, treatment and natural history of relevant paediatric and adult chronic GI and liver diseases dealt with in transition clinics.
- Centres should audit their population of AYP with chronic GI and liver diseases to determine the prevalence and service requirements for transition.

**Table 3** The estimated (and extrapolated) UK prevalence of chronic paediatric GI/liver conditions and number of patients transitioned each year using the best available epidemiological, audit and survey data as well as expert opinion.

<table>
<thead>
<tr>
<th>GI/liver condition</th>
<th>UK paediatric prevalence (total population or proportion within populations)</th>
<th>Estimated number of patients transitioned per year</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBD(^*)</td>
<td>7000 The prevalence of paediatric liver disease in England between 2008 and 2014: 11–15 years: 1502 16–17: 624(^\text{15})</td>
<td>1000 (~60% Crohn’s disease) Approximately 61–76 transplant cases per annum(^\text{18}) 753 paediatric patients were transferred to adult services between 2008 and 2014 (proportion which are non-transplant is unknown)(^\text{17})</td>
</tr>
<tr>
<td>Chronic liver disease</td>
<td>Complex enteral Parenteral nutrition (combination of long term in and out of hospital)</td>
<td>No relevant data identified No relevant data identified</td>
</tr>
<tr>
<td></td>
<td>Coeliac disease Allergic/eosinophilic oesophagitis Functional GI disease</td>
<td>3–13 per 1000 children, or approximately 1:80 to 1:300 children Food allergy 0.6%(^\text{6}) Eosinophilic oesophagitis 0.2 per 100 000 ~10%(^\text{5})</td>
</tr>
</tbody>
</table>

\(^*\) Estimates derived from the organisational IBD audit 2013 and local figures (RKR).\(^\text{16}\)

\(^{15}\) Williams et al.\(^\text{17}\)


\(^{18}\) Data courtesy of Henry Gowens/Andy Barclay British Intestinal Failure Survey data (unpublished 2014).
HCPs involved in the management of AYP with chronic GI and liver diseases should receive appropriate training in transition care such as the pitfalls and benefits of transition and strategies to improve transitional care.

- AYPs should be transitioned once they have finished or are in the later stages of puberty. Patients with growth issues should be transitioned once the growth issues are resolved.

RISK OF FAILING TRANSITION OR POOR TRANSITION

Transition to adulthood is a complicated process for most AYP and is particularly so where AYP have chronic illnesses and ongoing health needs. The transition process has increasingly been recognised as covering a vulnerable period where unaddressed healthcare needs may have long-term consequences.21

Inadequate transition arrangements and adverse outcomes

Inadequate transition arrangements have been associated with a number of adverse outcomes over a wide range of medical conditions including diabetes,22 23 heart disease,24 and haematological disorders.25 These consequences include delayed and inappropriate care, poor communication with AYP and their families, as well as emotional and often financial stress for patients, their families and healthcare systems. Following solid organ transplantation, inadequate transition has been associated with worsening adherence,26 increased graft loss27 and higher mortality.26 There have been few specific studies in gastroenterology and hepatology, but similar conclusions are emerging. Inadequate transition in IBD is associated with clinic non-attendance and non-adherence with medication, restricted growth potential and an increased likelihood of requiring surgery.28 In coeliac disease, inadequate transition arrangements are associated with dietary non-adherence, anaemia and reduced bone density.29

As the AYP grows into adulthood, considerations of further education and employment become important. There is some emerging data on the relevance of a coordinated transition during adolescence in chronic disorders, which may have impact on the future work and employment.30 31

Benefits of successful transition in other chronic diseases

There is evidence to support the benefits achieved by successful transition programmes in chronic diseases in various disciplines. For AYP with diabetes, successful transition has been shown to result in improved objective measures of glycaemic control, better engagement with screening programmes, improved outpatient attendance and engagement with adult providers in addition to decreased hospitalisation with diabetic ketoacidosis.32–35

In juvenile idiopathic arthritis and congenital heart disease, successful transition was associated with improved self-knowledge and improved disease knowledge among parents and carers. These were accompanied by increased satisfaction with the process and better quality of life.36 37 In renal diseases, an integrated paediatric-adult clinical transition service was associated with a striking reduction in the rate of graft loss among the patients with renal transplant.38

Evidence to document the impact of successful transition in gastroenterology and hepatology is more sparse. A recent UK study in 72 patients (diagnosed with IBD in paediatric care and then transferred to adult care service) who either went through a formal transition programme versus no formal programme has shown that establishment of a transition programme resulted in improvements in drug adherence, clinical attendance and growth with a reduced need for surgical intervention on retrospective analysis of their medical records.28 The same study also showed a trend towards improved growth pattern in the transition patients. A French group that performed a retrospective survey in 48 AYPs who had been transitioned from paediatric to adult care showed that a structured transition programme results in improved patients and carer satisfaction.39 Another study in which 81 AYPs with a chronic illness (34 IBD, 13 cystic fibrosis and 34 type 1 diabetes mellitus) were randomised to either a 2-month web-based text delivered health educational programme or a control group that received written materials health-related topics to read. It has shown disease management, health-related self-efficacy (one’s belief in one’s ability to accomplish a specific health-related task) and patient-initiated communications were all improved by the use of a generic disease management tool.40

Recommendations

We recommend the use of structured transition programmes to improve control of chronic GI disease in AYP (GRADE recommendation: strong (C)).

- We suggest that the use of structured transition programmes may increase disease-related knowledge in patients and carers/parents (GRADE recommendation: weak (C)).

- We suggest that a structured transition programme may improve psychological outcome and health-related quality of life in chronic GI diseases (GRADE recommendation: weak (D)).

- We suggest that the use of a structured transition programme may reduce adverse outcomes such as hospitalisation, surgery and radiation exposure in GI disease (GRADE recommendation: weak (C)).

Improvements in adherence and compliance

Following liver transplantation non-adherence to immunosuppression is a major cause of graft loss and mortality.26 41 Non-adherence increases throughout adolescence and may worsen when transfer is complete.26 The use of a dedicated transplant coordinator results in better adherence and improved self-management of healthcare needs. Thus, AYPs who had moved from paediatric to adult care after liver transplant with the support of a liver transplant coordinator had more appropriate tacrolimus levels and enhanced healthcare management parameters compared with a historical comparison group.42 Medication adherence in IBD also appears to be increased following a structured transition programme.28

Recommendation

We recommend the use of structured transition programmes to enhance adherence to medications, clinic attendance and clinical outcomes including organ survival in liver transplantation (GRADE recommendation: strong (C)).

MODELS OF AYP TRANSITION

The implementation of existing AYP transition models vary with differences in approach and outcome dependent on coordination between the relevant HCPs. Various models have been proposed and evaluated, but it remains unclear which transition model is associated with the best outcomes for AYP.34

Combined care during transition

Surveys of different transition programmes in a variety of medical disciplines have reported that combined clinic visits with input from both paediatric and adult HCPs are clinically beneficial and endorsed by patients. However, the exact format of transition may be highly variable and may include combined...
adult/paediatric clinics and/or joint multidisciplinary clinics or ‘virtual’ transition clinics.44

Recommendation
We suggest that an overlap between paediatric and adult gastroenterology care is a core element of every structured transition service (GRADE recommendation: weak (C)).

Benefit from AYP transition clinics in GI/liver diseases
Transition models incorporating a joint paediatric-adult clinic that have been associated with improvements in clinically relevant endpoints have been reported sparsely in gastroenterology and hepatology but there is supporting evidence from other chronic diseases that affect AYPs. For example in patients with renal transplant, a transition model in which the use of a single referral letter for transfer was replaced by an integrated paediatric-adult clinical service was associated with a reduction in the rate of graft loss.38 However, no significant enhancement of adherence, patient satisfaction or clinician’s subjective assessment of graft stability was reported in another small study of renal transplant recipients.45 In type 1 diabetes, significant improvements in HbA1c, rate of screening for complications of the disease and attendance at clinic appointments have been described in patients undergoing a structure transition planned and coordinated with the adult team compared with those in whom a letter of referral was used to transfer patients to the adult services.42

In a single-centre study from the UK where the transition clinic involved use of combined clinics with paediatric and adult gastroenterology teams and using assessment of readiness to transfer using tools, there were indicators for improvement in clinically relevant outcomes such as adherence, surgery rates and growth and development.15 In a further study from France, the majority of patients attending a joint paediatric and adult IBD clinic view a joint clinic as being beneficial in transferring information from their medical records and in building confidence in their new adult physician.19

Different transition models
The published guidance for specific models of transition lacks a strong evidence base and originates from expert opinion as a result of weak studies involving small patient numbers, bias and multiple methodological flaws within the data sets.32 44 46 47

However, a theoretical framework, entitled the Chronic Care Model (CCM), describes how teams comprised of individuals from different disciplines should approach the care of patients with chronic health conditions.48 It identifies the components of care that are relevant to transfer. The CCM also identifies the major barriers to a successful transfer including a lack of coordination between adult and paediatric services, a lack of planning and resistance of patient and families to transition of their healthcare. These themes were also identified in the UK survey on transition care among paediatric and adult gastroenterologists involved in care of AYPs.1 A description of the application of this model to a paediatric liver transplant population has been published and illustrates how a theoretical framework can be applied to implement organisational change.49

In a systematic review of practices that promote continuity between child and adult services, recurring themes within the literature were identified from which core principles of transition could be established. From this, four models of transition were outlined (direct, sequential, developmental and professional).50 In the ‘direct’ model, the focus is primarily on relations between services and addresses continuity of information between them, rather than focusing on the AYPs’ personal growth and development. The ‘sequential’ model is more flexible and recognises that the AYPs’ needs are changing and that they require some preparation if they are to adjust to adult care successfully. A ‘developmental’ transitional model starts from the premise that the AYP will need some help in acquiring the skills and support systems necessary to use or experience adult care effectively, with an active focus on personal growth and development. Finally, in contrast to the other models, the ‘professional’ model focuses on the expertise from within one service type (adult or paediatric) and not on the AYP. This may be important in conditions with a short life expectancy or where expertise is heavily located within one service, for example, cystic fibrosis, so is less applicable to chronic GI disease. These models are not mutually exclusive with this guideline reflecting aspects of all of these models in our recommendations but no evidence to support a particular type exclusively.

Recommendation
We suggest that while there are numerous models of transition there is no evidence to support a particular type (GRADE recommendation: weak (C)).

Essential components of AYP transition clinics
It is important to design the transition process to be flexible and dependent on patient factors including chronological age, current disease activity, adherence with medical therapies, views of AYP, view of the parents/caregivers and self-advocacy skills of the patient. The crucial role of a named transition coordinator (eg, for patients with IBD the paediatric IBD nurse who will remain a constant contact and organise the transition process) is a recurring theme in the literature and often scored as the key component of the programme in many surveys.13 35 46 51 52

A systematic review of transition services between paediatric and adult healthcare identified three core areas that require attention when developing a successful transition service. These comprised interventions aimed at staffing requirements (transition coordinator) and service delivery (separate young adult clinics, out-of-hours telephone support and enhanced follow-up) and patients (educational programmes and skills training).33

AYP transition coordinator
The AYP transition coordinator is frequently a specialist nurse, often, but not exclusively based within the paediatric service.53 54 However, an expanded role of the transition coordinator has also been described and applied to patients who have undergone liver transplantation.55 In this model, the transition coordinator continues to work with the patients after transfer to the adult services to help address gaps identified in the patients’ healthcare management.

Assessment of readiness to transfer
Several tools that assess the readiness to transfer have been described some of which are disease-specific.56–61 The Transition Readiness Assessment Questionnaire is a generic tool that has a high internal consistency and validity.60 The University of North Carolina TR(x)ANSITION Scale is a tool for assessing the effectiveness of a transition process.57 It uses a semi-structured interview with the patient with use of the medical records to verify data. It has a high inter-rater reliability. These tools tend to focus on patients’ knowledge of disease and skills. Psychometric data are not frequently collected. Data demonstrating the ability of these tools to predict outcomes of transition are lacking.62 The involvement of parents who can
overestimate AYP self-efficacy and have higher levels of anxiety than the AYP is deemed important.

Disease-specific education programmes

A number of tools may be used to facilitate disease education for transitioning patients. The ‘IBD passport’ (a wallet-sized card containing personal and medical information about the patient) has been identified as such a tool for transitioning AYPs with IBD by identifying the areas of weakness in which AYPs and parents require education and support such as awareness of disease pathogenesis, disease location, characteristics, medications and health resources available to them. In a pilot study of a disease-specific education programme in liver transplant recipients, a two-session education programme was associated with improvements in adherence to immunosuppressant medications and a reduction in elevated alanine aminotransferase (ALT) levels. In the first session, the focus was on educating the patient and parents on their disease and the medication regimens necessary to achieve disease control, while the second session focused on practical aspects of taking responsibility for one’s care in relation to taking medications, scheduling appointments, communicating directly to healthcare providers and attending appointments alone.

The use of education programmes to facilitate the transition process has been described in other chronic conditions. Disease-specific education programmes and skills training have been associated with improvement in HbA1c, acute complications, self-management skills and disease-specific knowledge in patients with diabetes transitioning to the adult services. However, no improvement in quality-of-life scores was demonstrated. In patients with juvenile idiopathic arthritis, an age-adjusted structured transition programme that featured a disease-specific programme of education was associated with an improvement in disease-specific quality of life and continuous improvements in knowledge of patients and their parents. No impact was demonstrated on independent health behaviours.

Furthermore, disease education for HCPs is a vital component of successful transition. A survey of adult and paediatric gastroenterologists in IBD identified suboptimal training in adolescent care in 65% and 59% respectively as a barrier to successful transition.

**Recommendation**

We recommend an effective transition model (figure 1) may benefit from inclusion of the following elements (GRADE recommendation: strong (D)):

A. flexible timing of transition
B. a named transition coordinator to oversee the process
C. individualisation of the transition model based on local expertise, staffing, resources and geography
D. assessment of readiness for transfer
E. disease-specific education programme.

We have suggested a transition pathway (figure 2) within this guideline incorporating many of the recommendations and practice points into a practical overview.

**Use of technology in AYP transition programmes**

Recent studies have highlighted the impact and interest in web-based and mobile technologies to assist in the transition process. Such technologies offer several unique advantages including potential for individualisation of the health message being delivered, anonymity, rapid access, low cost and ability to overcome most geographical barriers. With wireless technologies now being ubiquitous and text messaging being one of the main forms of communication by adolescents today, we suggest that such technology should be incorporated into the design of transition models to enable good, rapid communication with health providers for reporting of symptoms, obtaining essential medications, ensuring appointments are not missed, as well as providing links to educational materials and useful websites and support forums. In AYP with type 1 diabetes, the use of mobile phone interventions have resulted in improved clinic attendance, supported intensive insulin regimens and reduced progression from ketosis to diabetic ketoacidosis in those with poor glycaemic control.

A transition intervention for chronic disease (MD2Me) has been tested in a number of chronic diseases including IBD. This intervention uses technology-based communication between the healthcare team and patients (web-based and text message-based intervention) to enhance access to the healthcare team and to provide disease management and skills-based interventions. In a randomised controlled trial, this has been shown to improve health-related self-efficacy, performance of disease management tasks and patient-initiated communications. However, no beneficial impact was demonstrated for quality-of-life measure, functional performance or for disease status.

**Recommendations**

We recommend information technology as an effective and cost-efficient tool to facilitate transition (GRADE recommendation: strong (C)).

We recommend that AYP’s self-efficacy is enhanced by the use of virtual intervention and electronic communication (GRADE recommendation: strong (C)).

**Audit of transition programmes and research into their impact**

In view of the inability to recommend one specific transition model for any specific service, we suggest regular clinical audit of the transition process to identify weaknesses and facilitate

---

**Figure 1** Diagrammatic illustration of the different components an effective transition model should include.
improvements in the process for the benefit of HCPs, patients and carers alike. This would benefit from agreeing on key performance indicators for transition generally that are then complemented by disease-specific indicators. Audit should include assessment of the number of eligible patients that access a transition programme in addition to an assessment of the impact of the programme and patient satisfaction. The impact can be assessed using validated measures of disease-related knowledge and tools that assess progress through the transition process. Research into the impact of a successful transition

Figure 2  A transition pathway from paediatric to adult care for adolescent and young person (AYP) patients with chronic digestive disorders. MDT, multidisciplinary team.


Guidelines


Guidelines


Guidelines
programme is also required, which may include standard transition workshops that take place prior to and during the transition process.72 The rate of hospital admissions, use of support services, attendance at outpatient clinic appointments, requirement for steroids, adherence to medications and patient satisfaction would all be potential outcome measures for assessment of the impact of a transition intervention.67 Qualitative studies that assess the outcome of transition from a patient and parent perspective are also important. It is unlikely that a controlled trial in this area will be performed due to methodological difficulties in designing an appropriate trial as well as ethical concerns of allocating a group of patients to ‘no transition’ when all expert consensus suggests that this is inferior. Therefore, it is likely that research will assess outcomes between centres that offer transition compared with those that do not. This will always suffer from bias.

**Recommendation**

We recommend regular audit of the transition service in order to improve the service, outcomes and assess key performance indicators (GRADE recommendation: strong (D)).

**PATIENT AND CARER/PARENT PERSPECTIVE IN AYP TRANSITION**

**Addressing patient and carers/parents readiness during transition**

Anticipation of the timing of transition for AYPs has been identified as one of the most important factors for its success.73 74 AYPs with non-GI chronic disease report frustration at inflexibility regarding a determined age of transfer.75 76 In a study of 28 AYPs with a variety of chronic conditions, AYPs did not identify self-management as an indicator of readiness for transition and some transition occurred before they were willing, or understood the need.77 In patients with cystic fibrosis up to 12 months post transition, AYPs felt that paediatric HCPs were more concerned with the clinical parameters than the emotional factors associated with transition, reporting feeling neglected in this period while waiting for the move and being uncertain as to who was responsible for their healthcare needs during this period.78

**Patient and carer/parents uncertainty and behaviour during transition**

AYPs with IBD may feel a sense of abandonment or be uncertain regarding transfer to adult care79 while parents often feel a sense of anxiety about joining a new healthcare team that may not have been adequately informed about their condition.80 81 Furthermore, failure to connect with an adult healthcare provider post transition has been demonstrated to predict future complications in diabetic patients.82

AYPs often face multiple transitions (education, employment) at this stage in their lives, which may take priority over their healthcare transition resulting in anxiety and uncertainty.78 In this context, AYP may display regressive behaviour during transition82 and as a result transition services should identify this and provide supporting emotional and psychological support. Age, gender or severity of disease does not predict level of concern about transition in cystic fibrosis AYPs and their carers/parents.83

The combination of difficult symptoms and use of medications with significant side effects such as corticosteroids results in adolescents with IBD reporting poorer quality of life and an increased prevalence of psychological distress and depression.83 84 The most common coping strategy employed by AYP is ‘avoidant coping’; where an individual directs himself or herself with social diversion.85 This behaviour is associated with disease relapse in adolescents.86 A number of studies show improvement in adolescents overall psychological well-being with psychological interventions indicating an important role for the psychologist in IBD.87

**Recommendation**

We suggest that HCPs consider concerns of AYP and their carers/parents during transition and identify when additional emotional and psychological support is required (GRADE recommendation: weak (D)).

**Empowering AYPs self-management: the role of the patient and carers/parents**

Carers/parents of AYP undergoing transition may find it difficult to cope with their reduced role in medical care and should be actively included where appropriate.78 79 Carer/parent protectiveness has been reported as a significant challenge in transition in patient with juvenile idiopathic arthritis.89 Furthermore, HCPs may perceive AYPs ready to be seen independent of their carers/parents at an earlier age than their carers/parents do.90 Negotiating the appropriate level of protectiveness with carer/parent should be based on the AYPs self-efficacy and is an important skill for HCPs to appreciate.90

Addressing motivational issues, teaching problem-solving skills and addressing problematic patterns of family functioning are more likely to benefit individuals displaying intentional non-adherence.91 92 AYPs displaying non-adherence may benefit from more frequent appointments, with intensified clinical interventions.93

**RECOMMENDATIONS**

We suggest that HCPs maintain the goal of empowering the AYP to become independent while acknowledging the carer/parent perspectives (GRADE recommendation: weak (C)).

We recommend that AYPs identified as at risk of non-adherence may benefit from targeted specific educational and organisational interventions (GRADE recommendation: strong (C)).

**Disease-specific information appropriate for developmental age and gender**

Disease-specific knowledge is an important part of AYP transition but information given is not always pertinent to AYPs stage of development,89 93 with information more often geared towards the carers/parents rather than AYPs.94 AYPs are taking over self-management later than expected from carers/parents,95 with those >18 years often requiring significant assistance from carers/parents to book clinic appointments and order medications.96 Furthermore, the age of disease onset and timing of medical interventions may play a role in mastery over healthcare responsibilities. In liver transplantation, younger male recipients struggled more with mastery over their healthcare compared with those transplanted at an older aged and to females in any age group.97

An organised transition programme should include age-specific educational components to address the deficits in AYP knowledge.88 Acquisition of skills needed for successful transition should be a stepwise or age appropriate checklist for the AYP.92 93 94 95 In IBD, a ‘transition protocol’ has been developed by Hait et al.74 which is based around developmental milestones to anticipate the changes and normal expectations for AYP for self-management and self-efficacy whereby at different ages (11–13, 14–16, 17–19 and 20–23 years old) a checklist
of tasks for the medical team (eg, at 11–13 years old, HCP introduces concept of future independent visits to the HCP) and milestones for the AYP (eg, 14–16 years old, AYP knows their own medical history) are gradually obtained on the protocol. However, this does not recognise the variable rate for maturity and developmental milestones, with its inflexible format being its major limitation.

RECOMMENDATION
We recommend that disease-specific information and education be appropriate for the AYPs developmental stage and this should be reassessed over the period of transition (GRADE recommendation: strong (C)).

Lifestyle, psychosocial health and sexuality
Studies in transplant recipients demonstrate that AYPs wish to be treated as adults and prefer healthcare professionals to address them instead of their parents. In addition, these studies have identified that areas that may not be addressed in a paediatric setting such as sexual relationships and recreational drug use are important to AYPs, but they are often reluctant to ask for such information.21 80 101

AYPs are often concerned that their illness will compromise their employment and preclude them from valued jobs. In a qualitative study of cystic fibrosis and congenital heart disease, AYPs and their carers/parents describe seeing the future as uncertain, with particular concern regarding deteriorating health and occupational restrictions in the future. Employment issues are one of the primary sources of stress for cystic fibrosis AYPs in transition.102

AYPs with GI disease report major concerns regarding body image and HCPs may encounter resistance to the use of corticosteroids in the transition period.103 AYPs with IBD also describe concerns relating to future fertility104 and a sense of potential loss regarding normal gendered roles such as motherhood.102 Similarly AYPs with juvenile idiopathic arthritis express concern over disclosing illness to sexual partners.89 105 Furthermore, AYPs’ liver transplant recipients express concern about transmitting illness to descendants with concern regarding immunosuppression on fertility and future children’s health and demonstrating a lack of understanding of genetic risk.106 Furthermore, AYPs may not feel doctors understand the wider impact on their life.89 105

Recommendation
We suggest the transition process addresses the AYP’s lifestyle, future health concerns, educational/employment goals, psychosocial health, sexuality and reproduction (GRADE recommendation: weak (D)).

SURGICAL PERSPECTIVE
There is limited data in relation to transition of AYP in the field of surgery. There are several groups of patients that may benefit from transition from paediatric to adult care:

1. Patients who have undergone surgery in a specialist paediatric unit who require long-term follow-up and have reached an age where care in a paediatric setting is no longer inappropriate.
2. Patients who have been receiving ongoing paediatric medical treatment for a condition requiring surgical intervention at an age on the cusp of needing transition to an adult surgical service.

3. Patients with newly diagnosed conditions needing surgical intervention diagnosed at an age where transition to an adult service is indicated.

While it would be possible for AYPs in the above groups to be seen in a regular adult surgical outpatient setting, this would require initiating a new dialogue with the adult surgeon. AYPs and parents/carers may find the adult clinic setting an intimidating experience compared with the more familiar paediatric environment.

In a surgical gastroenterological transition clinic, the paediatric surgeon can hand the case over to his adult surgeon colleague. This may entail not only describing in detail the procedures already performed by the paediatric surgeon but also the nuances around any family dynamics and aspects of the patients psyche. This will enable robust transfer of anatomical surgical knowledge and engendering confidence in the receiving surgeon, AYP and parent/carers. In specific cases, it may also be appropriate for the adult surgeon to consider operating jointly with the paediatric surgeon if the AYP is not yet ready for transition.

Practice point
- We suggest that AYPs who require surgical intervention during the transition period have a named adult surgeon in the disciplined concerned involved in their care preoperatively, peroperatively and postoperatively, and that surgeon will form part of the multidisciplinary team in transition care.

CONCLUSION
This guideline provides the framework for healthcare professionals to develop transition services for patients with chronic GI disorders, using the best available research data from the literature related to AYPs with GI disorders and other chronic disorders in which transition between paediatric and adult health services is routinely done. The most significant limitation of this review is that the recommendations are predominantly based on evidence graded as weak due to the paucity of randomised controlled trials in this area. In addition, there is a significant lack of GI-specific data in this expanding field and hence recommendations are based on evidence not exclusively pertinent to GI-specific research. Future studies are needed to improve the strength of recommendations for future revisions of the guidelines. Furthermore, future research must consider design to improve outcome-based data with longitudinal design in order to aid future cost-benefit analysis to be undertaken. Our hope is that this guideline will stimulate more GI-related research in this field so future revisions will be supported by an expanding robust and broad evidence base.

SCHEDULED REVIEW OF GUIDELINES
The proposed date for review is 1 August 2021 to take account new developments in this area and as set out in the ‘BSG Guideline Advice’ document.7 Every two years the research objectives identified in the guidelines will be reviewed for evidence of additional studies, which may contribute to resolving the objectives. The guidelines are available on the BSG website (http://www.bsg.org.uk) and listed by date of publication. These guidelines are accessible to the public. There is a forum for feedback from BSG members via the forum link in the members’ area on the BSG website to ensure there is a facility for feedback after publications. Any publication updates maybe published in Gut as a letter subject to the normal review processes of the journal and are submitted to the CSSC Secretary/Guidelines.
Editor who arranges a peer review by the CSSC prior to submission to *Gut*.

**Author affiliations**

1. Academic Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK
2. Centre for Gastroenterology and Hepatology, Royal Free Hospital, London, UK
3. Department of Surgery, UCLH, London, UK
4. Royal Liverpool University Hospital, Liverpool, UK
5. Queen Elizabeth Hospital NHS Foundation Trust, University of East Anglia, King's Lynn, Norfolk, UK
6. Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK
7. Glasgow Royal Infirmary, Glasgow, UK
8. Department of Gastroenterology, Royal Victoria Hospital, Belfast, UK
9. Liver Unit, Birmingham Children’s Hospital, Birmingham, UK
11. Queen Elizabeth Hospital Birmingham NHS Foundation Trust, Birmingham, UK
12. GI Services Division, University College London Hospital, London, UK
13. London, UK
14. Department of Paediatric Gastroenterology, The Royal Hospital for Children Glasgow, Glasgow, UK
15. Department of Gastroenterology, UCLH, London, UK
16. Bart’s Health NHS Trust, The Royal London Hospital, London, UK
17. Centre for Immunology and Infectious Disease, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, UK

**Twitter**

Follow Alenka Brooks @alenkabrooks and Philip Smith @drphilipjsmith

**Acknowledgements**

BSG Adolescent and Young Person Section 2013–2015, Ms Stephanie Cort, a BSG staff member who provided invaluable assistance with guideline production. The authors like to thank Mrs Sarah Macdonald, Principal Dietician and Simone Cort, a BSG staff member who provided invaluable assistance with guideline production. The authors like to thank Mrs Sarah Macdonald, Principal Dietician and Simone Cort, a BSG staff member who provided invaluable assistance with guideline production.

The authors like to thank Mrs Sarah Macdonald, Principal Dietician and Simone Cort, a BSG staff member who provided invaluable assistance with guideline production.

**Provenance and peer review**

This paper was first published as 10.1136/gutjnl-2016-313000 on 21 February 2017. Downloaded from http://gut.bmj.com/ on September 1, 2021 by guest. Protected by copyright.

**REFERENCES**


EDITOR’S QUIZ: GI SNAPSHOT

A rare cause of GI bleeding in a 56-year-old man

A 56-year-old man, with a known history of diabetes for 1 year, presented with a 5-day history of melena that was associated with one episode of haematemesis. One month prior, he had completed a course of oral amoxicillin for a dental infection that occurred after a tooth extraction. The only other significant past medical problem was hypertension for 10 years. Physical examination only showed pallor and abdominal examination was normal. Laboratory investigations revealed haemoglobin level of 8.4 g/dL and HbA1C of 7.8%. His upper GI endoscopy showed a diffuse irregular friable exudative ulcerative lesion involving the gastric fundus (figure 1). Endoscopic ultrasonography (EUS) demonstrated disrupted gastric wall layers with wall thickening of 5.1 mm and regional lymph nodes (figure 2).

Abdominal CT also showed gastric wall thickening and cluster of regional lymph nodes (figure 3). Upper GI series showed a focal irregular mucosal pattern with relatively flattened gastric fundus.

QUESTION
What is the most likely diagnosis?

See page 1074 for answer